Background—Early reinfarction after thrombolytic therapy is associated with adverse
outcomes and increased mortality. Among patients with reinfarction in the 1992 Global …

Numerous controlled clinical trials have documented the efficacy of thrombolytic agents in
reducing the risk of mortality after myocardial infarction (MI). As a result, it is no longer ethical …

Thrombolytic therapy remains a mainstay for the treatment of patients with acute myocardial
infarction. This therapy has been the subject of intense investigation and multiple studies as …

Background The Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
(GUSTO-I) trial was designed to test whether thrombolytic strategies achieving more …

Evidence of the potential impact of intravenous thrombolytic therapy on short-term
revascularization rates among patients with acute myocardial infarction was sought …

To compare the results and outcome of different management approaches for acute
myocardial infarction, we analyzed our experience with early (ie, within 6 hours of infarct …

Several modes of reperfusion therapy for evolving myocardial infarction (MI) have been
developed, which differ in terms of effectiveness, complexity and costs. Reperfusion …

Background—New recombinant plasminogen activators have been developed to simulate
the fibrinolytic action of the physiological serine protease tissue plasminogen activator …

Patients with failure of infarct-related artery recanalization after thrombolytic therapy have a
poor clinical outcome. These patients have been considered for rescue angioplasty 90 min …

With the establishment of thrombosis as the cause of myocardial infarction, the pivotal role of
thrombolytics and primary angioplasty has evolved. Large randomized trials with innovative …